BR1019 1
Alternative Names: BR1019-1; BR1019A; BR1019A-1Latest Information Update: 30 May 2024
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperglycaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 21 May 2024 Phase-III clinical trials in Hypertension (Combination therapy) in South Korea (PO) (NCT06220773)
- 21 May 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Combination therapy) in South Korea (PO) (NCT06220773)
- 31 Mar 2024 Boryung Pharmaceutical completes a phase I trial for Hypertension and Type 2 Diabetes Mellitus (In volunteers) in South Korea (PO) (NCT06226727)